Logo image of CRBP

CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Fundamental Analysis

USA - NASDAQ:CRBP - US21833P3010 - Common Stock

14.83 USD
+1.82 (+13.99%)
Last: 10/3/2025, 8:00:01 PM
14.98 USD
+0.15 (+1.01%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CRBP. CRBP was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRBP as it has an excellent financial health rating, but there are worries on the profitability. CRBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRBP had negative earnings in the past year.
In the past year CRBP has reported a negative cash flow from operations.
CRBP had negative earnings in each of the past 5 years.
CRBP had a negative operating cash flow in each of the past 5 years.
CRBP Yearly Net Income VS EBIT VS OCF VS FCFCRBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CRBP has a Return On Assets (-46.33%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -52.21%, CRBP is in the better half of the industry, outperforming 65.49% of the companies in the same industry.
Industry RankSector Rank
ROA -46.33%
ROE -52.21%
ROIC N/A
ROA(3y)-82.9%
ROA(5y)-79.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRBP Yearly ROA, ROE, ROICCRBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

CRBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBP Yearly Profit, Operating, Gross MarginsCRBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for CRBP has been increased compared to 1 year ago.
Compared to 5 years ago, CRBP has more shares outstanding
There is no outstanding debt for CRBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRBP Yearly Shares OutstandingCRBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CRBP Yearly Total Debt VS Total AssetsCRBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.35, we must say that CRBP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.35, CRBP is in the better half of the industry, outperforming 60.82% of the companies in the same industry.
CRBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACCN/A
CRBP Yearly LT Debt VS Equity VS FCFCRBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 9.21 indicates that CRBP has no problem at all paying its short term obligations.
CRBP has a better Current ratio (9.21) than 78.36% of its industry peers.
A Quick Ratio of 9.21 indicates that CRBP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.21, CRBP is in the better half of the industry, outperforming 78.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.21
Quick Ratio 9.21
CRBP Yearly Current Assets VS Current LiabilitesCRBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

CRBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.85%, which is quite good.
EPS 1Y (TTM)14.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRBP will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.78% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-78.36%
EPS Next 2Y-21.02%
EPS Next 3Y-20.29%
EPS Next 5Y-10.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP Yearly Revenue VS EstimatesCRBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CRBP Yearly EPS VS EstimatesCRBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBP Price Earnings VS Forward Price EarningsCRBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP Per share dataCRBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A cheap valuation may be justified as CRBP's earnings are expected to decrease with -20.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.02%
EPS Next 3Y-20.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (10/3/2025, 8:00:01 PM)

After market: 14.98 +0.15 (+1.01%)

14.83

+1.82 (+13.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners72.28%
Inst Owner Change-28.91%
Ins Owners0.58%
Ins Owner Change0.36%
Market Cap181.82M
Analysts86.25
Price Target41.48 (179.7%)
Short Float %10.86%
Short Ratio9.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.08%
Min EPS beat(2)-6.46%
Max EPS beat(2)6.63%
EPS beat(4)2
Avg EPS beat(4)5.33%
Min EPS beat(4)-18.43%
Max EPS beat(4)39.57%
EPS beat(8)6
Avg EPS beat(8)12.45%
EPS beat(12)7
Avg EPS beat(12)7.21%
EPS beat(16)10
Avg EPS beat(16)7.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.6%
EPS NY rev (1m)0.21%
EPS NY rev (3m)-4.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-12.49%
Revenue NY rev (3m)-12.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-4.76
EYN/A
EPS(NY)-5.36
Fwd EYN/A
FCF(TTM)-4.72
FCFYN/A
OCF(TTM)-4.72
OCFYN/A
SpS0
BVpS9.05
TBVpS9.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.33%
ROE -52.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.9%
ROA(5y)-79.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.21
Quick Ratio 9.21
Altman-Z 0.35
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-78.36%
EPS Next 2Y-21.02%
EPS Next 3Y-20.29%
EPS Next 5Y-10.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-19.79%
EBIT Next 5Y-22.96%
FCF growth 1Y-53.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.68%
OCF growth 3YN/A
OCF growth 5YN/A